Sangeeta N. Bhatia net worth and biography

Sangeeta Bhatia Biography and Net Worth

Dr. Bhatia joined our board in 2015. She currently serves as the John J. and Dorothy Wilson Professor of Engineering at MIT, Director of the Marble Center for Cancer Nanomedicine, and an investigator for the Howard Hughes Medical Institute. She also holds appointments at the Koch Institute for Integrative Cancer Research, the Broad Institute, the Wyss Institute, and Brigham and Women’s Hospital. In 2018, Dr. Bhatia was on sabbatical from MIT while she served as a co-founder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring. Prior to joining MIT in 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego from 1998 through 2005. Dr. Bhatia holds a Sc.B. in Biomedical Engineering from Brown University, an S.M. in Mechanical Engineering and a Ph.D. in Biomedical Engineering from MIT, and an M.D. from Harvard Medical School. Dr. Bhatia was the 25th person in history to be an elected member of all three US National Academies: National Academy of Science, the National Academy of Medicine, and the National Academy of Engineering. She has been honored with the Lemelson-MIT Prize, the Heinz Medal, and the Othmer Gold Medal for groundbreaking inventions and advocacy for women in STEM fields.

What is Sangeeta N. Bhatia's net worth?: The estimated net worth of Sangeeta N. Bhatia is at least $1.53 million as of October 17th, 2023. Dr. Bhatia owns 3,901 shares of Vertex Pharmaceuticals stock worth more than $1,534,965 as of April 19th. This net worth evaluation does not reflect any other investments that Dr. Bhatia may own. Learn More about Sangeeta N. Bhatia's net worth.
How do I contact Sangeeta N. Bhatia?: The corporate mailing address for Dr. Bhatia and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Sangeeta N. Bhatia's contact information.
Has Sangeeta N. Bhatia been buying or selling shares of Vertex Pharmaceuticals?: Sangeeta N. Bhatia has not been actively trading shares of Vertex Pharmaceuticals in the last ninety days. Learn More on Sangeeta N. Bhatia's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 32 times. They sold a total of 115,042 shares worth more than $42,520,712.26. The most recent insider tranaction occured on February, 26th when EVP Ourania Tatsis sold 354 shares worth more than $150,697.80. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 2/26/2024.

Sangeeta N. Bhatia Insider Trading History at Vertex Pharmaceuticals

Sangeeta N. Bhatia Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $393.48

$391.02

$396.14

50 Day Range

MA: $414.17

$393.10

$433.48

2 Week Range

Now: $393.48

$316.43

$448.40

Volume

948,866 shs

Average Volume

1,245,130 shs

Market Capitalization

$101.70 billion

P/E Ratio

28.33

Dividend Yield

N/A

Beta

0.35

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…